Navigation Links
BiOptix announces expansion of Innovators Program into Europe
Date:9/26/2013

BOULDER, Colo. and BASEL, Switzerland, Sept. 26, 2013 /PRNewswire/ -- BiOptix formally announced the European expansion of the BiOptix Innovators Program at MipTec & BioValley Life Sciences Week, being held in Basel, Switzerland from September 24 – 26, 2013.  During the event, the company is launching the BiOptix Innovators Program into Europe, with an emphasis on partnering with key research institutions, pharmaceutical companies and biotechnology/drug discovery firms.  The BiOptix Innovators Program is a unique and innovative product evaluation platform that allows customers to try BiOptix SPR technology independently in their lab, on their timeframe and with complete customer and technical support during the evaluation. 

"This is the third year that BiOptix has participated in MipTec and the BioValley Life Sciences Week in Basel, and the 2013-2014 season brings an opportunity for us to expand our presence in this market with this distinctive program," noted Ken Wilczek, Vice President, Sales & Marketing for BiOptix.  "The life science research corridor in Europe is growing at a substantial rate, and we are excited to be a part of this expansion."  Additional details about the BiOptix Innovators Program can be found at: http://www.bioptix.com/products/innovators-program

Surface Plasmon Resonance is an advanced and highly sensitive optical technology that measures refractive index changes on a sensor chip's gold surface due to a change in mass that occurs during a binding event. This change can be used to monitor biological interactions such as the concentration of target molecules, kinetic rates and affinity constants. BiOptix has developed and patented a novel ultra-sensitive detection platform known as Enhanced Surface Plasmon resonance, or ESPR. Unlike traditional SPR, ESPR instrumentation from BiOptix enables the high sensitivity of SPR with the high stability and lower noise of common path interferometry.

About BiOptix
BiOptix Diagnostics is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures, Remeditex and Rusnano.  BiOptix has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR – Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction—with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at:  www.bioptix.com


'/>"/>
SOURCE BiOptix
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BiOptix announces low cost Surface Plasmon Resonance Services for Colorado-based researchers
2. BiOptix to highlight new carbonic anhydrase data at IBCs Biopharmaceutical Development & Production Week
3. BiOptix announces expansion of Innovators Program at Molecular Med TRI-CON 2013
4. BiOptix Announces Fall 2012 Tradeshow and Symposia Schedule
5. Ampio Pharmaceuticals, Inc. Announces $25 Million Financing
6. Lilly Announces Second Positive Ramucirumab Phase III Gastric Cancer Study Meets Primary Endpoint; Phase III Lilly/TRIO Breast Cancer Study Misses Primary Endpoint
7. Pro-Dex, Inc. Announces Fiscal 2013 Fourth Quarter And Full-Year Results
8. OralHygenix Announces Freedom Oral Care System (FOCS) for People with Physical and Mental Disabilities
9. STEMSOFT Announces Release of New Cord Banking Software Solution
10. PipelineRx Announces Expansion into Ten New States with Telepharmacy Services
11. Genarts 18th Annual Film Festival Announces Collaboration With The Partnership At Drugfree.org For #endmedicineabuse Project
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016 TapImmune,Inc. ... of innovative peptide and gene-based immunotherapeutics and vaccines for the ... be presenting at the 3rd Annual Growth Capital Expo ... th , 2016 at Caesars Palace in Las Vegas, Nevada.  ... on Wednesday, May 4 th by Dr. John ...
(Date:4/27/2016)...   , Total ... Consumable Sales  Clinical sales grow 16% year-over-year  ... MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal ... first quarter ended March 31, 2016 and provided an ... commercial strategy. First Quarter 2016 Revenue Results ...
(Date:4/27/2016)... SHAWNEE, Kan. , April 27, 2016 /PRNewswire/ ... Martabano , a senior from the University of ... winner of the Bayer Excellence in Communication Award ... veterinary schools, which were awarded a total of ... Over the last four years, Bayer has provided ...
Breaking Medicine Technology:
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... On Tuesday, ... hospitals across the Southeast, celebrated the signature of Gov. Nathan Deal on SB 258, ... Geoff Duncan (R - Cumming), offers a 70% tax credit to individuals and corporations ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House ... their loans, more information about their loan terms and accounts, and more protections ... debt, including federal and private loans, has reached $1.3 trillion, with 43 million ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... that infants born with severe congenital diaphragmatic hernia have better survival rates if ... congenital diaphragmatic hernia (CDH)—a condition where the diaphragm fails to form completely, letting ...
(Date:4/29/2016)... ... April 29, 2016 , ... Mobility Designed is ... pressure on the armpits, the M+D Crutch evenly distributes body weight from the elbow ... and hands when using the crutches than with other crutches. , Co-founders Max and ...
(Date:4/29/2016)... Tarzana, CA (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type ... is to blame for the majority of skin cancer deaths. More than 10,000 people are ... average age at diagnosis is 62, it is the one of the most commonly diagnosed ...
Breaking Medicine News(10 mins):